Brain Cancer Research

Standard radiation for medulloblastoma can cause long-term damage to a child’s developing brain. A new clinical trial suggests that the volume and dose of radiation could be safely tailored based on genetic features in the patient’s tumor.

In people with glioblastoma and other brain cancers, steroids appear to limit the effectiveness of immunotherapy drugs, a new study shows. The findings should influence how steroids are used to manage brain tumor symptoms, researchers said.

Results from two studies show that a liquid biopsy that analyzes DNA in blood accurately detected kidney cancer at early and more advanced stages and identified and classified different types of brain tumors.

A method that combines artificial intelligence with an advanced imaging technology can accurately diagnose brain tumors in fewer than 3 minutes during surgery, a new study shows. The approach can also accurately distinguish tumor from healthy tissue.

Glioblastoma cells sneak many copies of a key oncogene into circular pieces of DNA. In a new NCI-funded study, scientists found that the cells also slip several different genetic “on switches” into these DNA circles, helping to fuel the cancer’s growth.

Men and women with glioblastoma appear to respond differently to standard treatment. A new study identifies biological factors that might contribute to this sex difference.

A liquid biopsy blood test can detect DNA from brain tumors called diffuse midline gliomas, researchers have found. This minimally invasive test could be used to identify and follow molecular changes in children with these highly lethal brain tumors.

Despite continued efforts to develop new therapies for glioblastoma, none have been able to improve how long patients live appreciably. Despite some setbacks, researchers are hopeful that immunotherapy might be able to succeed where other therapies have not.

This phase 2 trial is testing standard therapy (surgery, radiation, and temozolomide) plus the checkpoint inhibitor pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.

Progress against the brain cancer glioblastoma has been slow. Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that.

Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.

Brain cancer cells are heavily dependent on a constant supply of cholesterol to survive, a new study suggests. And in mice with brain tumors, treatment with a cholesterol-depleting drug slowed tumor growth and improved survival.

Results from two clinical trials show that treating patients with the chemotherapy drug temozolomide in addition to radiation therapy increased overall and progression-free survival.

Changes in the packaging of DNA in the cell nucleus may activate growth-promoting genes that cause cancer.

A patient with a papillary craniopharyngioma saw his tumor shrink more than 80 percent after treatment with a targeted drug that inhibits a mutant form of the BRAF protein.

TCGA researchers analyzed nearly 300 cases of diffuse low- and intermediate-grade gliomas, which together comprise lower-grade gliomas. LGGs occur mainly in adults and include astrocytomas, oligodendrogliomas and oligoastrocytomas.

NCI's Dr. Mark Gilbert discusses new developments in neuro-oncology and the priorities of the Neuro-Oncology Branch.